TY - JOUR
T1 - Nano-sized polymers and liposomes designed to deliver combination therapy for cancer
AU - Eldar-Boock, Anat
AU - Polyak, Dina
AU - Scomparin, Anna
AU - Satchi-Fainaro, Ronit
N1 - Funding Information: The Satchi-Fainaro research laboratory is partially supported by The Association for International Cancer Research (AICR), German-Israel Foundation (GIF), Rimonim Consortium and the MAGNET Program of the Office of the Chief Scientist of the Israel Ministry of Industry, Trade & Labor, THE ISRAEL SCIENCE FOUNDATION (Grant No. 1309/10), the United States-Israel Binational Science Foundation (Grant No. 2007347), Swiss Bridge Award, and by grants from the Israeli National Nanotechnology Initiative, Focal Technology Area (FTA) program: Nanomedicine for Personalized Theranostics, and by The Leona M. and Harry B. Helmsley Nanotechnology Research Fund.
PY - 2013/8
Y1 - 2013/8
N2 - The standard of care for cancer patients comprises more than one therapeutic agent. Treatment is complex since several drugs, administered by different routes, need to be coordinated, taking into consideration their side effects and mechanisms of resistance. Drug delivery systems (DDS), such as polymers and liposomes, are designed to improve the pharmacokinetics and efficacy of bioactive agents (drugs, proteins or oligonucleotides), while reducing systemic toxicity. Using DDS for co-delivery of several agents holds great potential since it targets simultaneously synergistic therapeutic agents increasing their selective accumulation at the tumor site and enhancing their activity allowing administration of lower doses of each agent, thus reducing their side effects. Taken together, implementation of smart DDS will hopefully result in increased patient's compliance and better outcome. This review will focus on the latest developments of combination therapy for cancer using DDS.
AB - The standard of care for cancer patients comprises more than one therapeutic agent. Treatment is complex since several drugs, administered by different routes, need to be coordinated, taking into consideration their side effects and mechanisms of resistance. Drug delivery systems (DDS), such as polymers and liposomes, are designed to improve the pharmacokinetics and efficacy of bioactive agents (drugs, proteins or oligonucleotides), while reducing systemic toxicity. Using DDS for co-delivery of several agents holds great potential since it targets simultaneously synergistic therapeutic agents increasing their selective accumulation at the tumor site and enhancing their activity allowing administration of lower doses of each agent, thus reducing their side effects. Taken together, implementation of smart DDS will hopefully result in increased patient's compliance and better outcome. This review will focus on the latest developments of combination therapy for cancer using DDS.
UR - http://www.scopus.com/inward/record.url?scp=84880930108&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.copbio.2013.04.014
DO - https://doi.org/10.1016/j.copbio.2013.04.014
M3 - مقالة مرجعية
C2 - 23726153
SN - 0958-1669
VL - 24
SP - 682
EP - 689
JO - Current Opinion in Biotechnology
JF - Current Opinion in Biotechnology
IS - 4
ER -
